Paradigm Biopharmaceuticals Limited (PAR.AX)
AUD 0.37
(-2.67%)
AUD 0.37
(-2.67%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 65.8 Thousand | 46.76 Thousand | 79.22 Thousand | 20.55 Thousand | - | 2.98 Million |
| Cost of Revenue | 8988.00 | 172.48 Thousand | 337 Thousand | 309.19 Thousand | 213.11 Thousand | 8348.00 |
| Gross Profit | 56.81 Thousand | -125.72 Thousand | -257.77 Thousand | -288.64 Thousand | -213.11 Thousand | 2.97 Million |
| Operating Expenses | 65.1 Million | 59.09 Million | 46.75 Million | 42.05 Million | 16.74 Million | 11.93 Million |
| Selling, General and Administrative Expenses | 6.76 Million | 6.41 Million | 7.74 Million | 8.53 Million | 3.95 Million | 4.03 Million |
| Research and Development Expenses | 58.33 Million | 52.67 Million | 39.01 Million | 33.51 Million | 12.79 Million | 7.89 Million |
| Other Expenses | - | 6.74 Million | 8.65 Million | 8.71 Million | 3.69 Million | 1.25 Million |
| Cost and Expenses | 65.11 Million | 59.26 Million | 47.08 Million | 42.36 Million | 16.96 Million | 11.94 Million |
| Operating Income | -65.11 Million | -59.21 Million | -47.01 Million | -42.34 Million | -16.96 Million | -11.94 Million |
| Interest Expense | 14.37 Thousand | 16.41 Thousand | 28.63 Thousand | 37.72 Thousand | 34.16 Thousand | - |
| Income Tax Expense | -6.04 Million | -7.04 Million | -7.76 Million | -8.34 Million | -3.64 Million | -2.98 Million |
| Earnings before Tax | -64.7 Million | -58.95 Million | -47.01 Million | -42.64 Million | -15.94 Million | -18.61 Million |
| Net Income | -58.65 Million | -51.91 Million | -39.24 Million | -34.29 Million | -12.29 Million | -15.62 Million |
| Earnings Per Share Basic | -0.20 | -0.18 | -0.16 | -0.16 | -0.06 | -0.11 |
| Earnings Per Share Diluted | -0.20 | -0.18 | -0.16 | -0.16 | -0.06 | -0.11 |
| Weighted Average Shares Outstanding | 293.28 Million | 289.67 Million | 240.96 Million | 212.19 Million | 208.26 Million | 148.13 Million |
| Weighted Average Shares Outstanding (Diluted) | 293.28 Million | 289.67 Million | 241.81 Million | 212.19 Million | 208.26 Million | 148.13 Million |
| Gross Margin | 0.86 | -2.69 | -3.25 | -14.05 | - | 1.00 |
| EBIT Margin | -980.84 | -1263.09 | -590.95 | -2050.30 | - | -4.00 |
| Profit Margin | -891.39 | -1110.14 | -495.43 | -1668.96 | - | -5.24 |
| EBITDA | -64.53 Million | -59.06 Million | -46.81 Million | -42.13 Million | -15.69 Million | -8.95 Million |
| Earnings Before Tax Margin | -989.55 | -1266.38 | -593.39 | -2060.52 | - | -4.00 |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 65.8 Thousand | 65.8 Thousand | - | 42.05 Thousand | 46.76 Thousand | 4710.00 |
| Cost of Revenue | 155.72 Thousand | 8988.00 | 73.39 Thousand | 88.22 Thousand | 172.48 Thousand | 84.26 Thousand |
| Gross Profit | -89.92 Thousand | 56.81 Thousand | -73.39 Thousand | -46.17 Thousand | -125.72 Thousand | -79.55 Thousand |
| Operating Expenses | 64.4 Million | 14.95 Million | 49.82 Million | 26.87 Million | 59.09 Million | 32.21 Million |
| Selling, General and Administrative Expenses | - | 2.99 Million | 3.44 Million | 1.92 Million | - | 4.48 Million |
| Research and Development Expenses | - | 11.95 Million | 46.37 Million | 24.94 Million | - | 27.72 Million |
| Other Expenses | - | - | - | - | 6.74 Million | - |
| Cost and Expenses | 64.55 Million | 14.96 Million | 49.89 Million | 26.96 Million | 59.26 Million | 32.3 Million |
| Operating Income | -64.49 Million | -14.96 Million | -49.89 Million | -26.91 Million | -59.21 Million | -32.29 Million |
| Interest Expense | 14.37 Thousand | 7891.00 | 6479.00 | 7662.00 | 16.41 Thousand | 8754.00 |
| Income Tax Expense | -6.04 Million | -4.98 Million | -1.06 Million | -6.26 Million | -7.04 Million | -775.89 Thousand |
| Earnings before Tax | -64.7 Million | -9.69 Million | -50.01 Million | -26.3 Million | -58.95 Million | -32.64 Million |
| Net Income | -58.65 Million | -9.69 Million | -48.95 Million | -20.04 Million | -51.91 Million | -31.86 Million |
| Earnings Per Share Basic | - | -0.03 | -0.16 | -0.07 | - | -0.12 |
| Earnings Per Share Diluted | - | -0.03 | -0.16 | -0.07 | - | -0.12 |
| Weighted Average Shares Outstanding | 293.28 Million | 286.59 Million | 299.78 Million | 289.67 Million | 289.67 Million | 276.78 Million |
| Weighted Average Shares Outstanding (Diluted) | 293.28 Million | 286.77 Million | 299.78 Million | 289.67 Million | 289.67 Million | 276.78 Million |
| Gross Margin | -1.37 | 0.86 | - | -1.10 | -2.69 | -16.89 |
| EBIT Margin | - | -226.32 | - | -638.36 | - | -6840.54 |
| Profit Margin | -891.39 | -147.34 | - | -476.64 | -1110.14 | -6765.91 |
| EBITDA | - | -14.89 Million | -49.82 Million | -26.84 Million | - | -32.21 Million |
| Earnings Before Tax Margin | -980.13 | -227.44 | - | -640.19 | -1266.38 | -6856.86 |
RNFT
SCTSF
0298
PREV-B
OPN
SNV-PD